» Articles » PMID: 37512804

Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?

Abstract

Localized cutaneous leishmaniasis caused by can either respond well or poorly to the treatment or heal spontaneously; It seems to be dependent on the parasite and/or host factors, but the mechanisms are not fully understood. We evaluated the in situ immune response in eighty-two active lesions from fifty-eight patients prior to treatment classified as early spontaneous regression (SRL-n = 14); treatment responders (GRL-n = 20); and non-responders (before first treatment/relapse, PRL1/PRL2-n = 24 each). Immunohistochemistry was used to identify cell/functional markers which were correlated with the clinical characteristics. PRL showed significant differences in lesion number/size, clinical evolution, and positive parasitological examinations when compared with the other groups. SRL presented a more efficient immune response than GRL and PRL, with higher IFN-γ/NOS2 and a lower percentage of macrophages, neutrophils, NK, B cells, and Ki-67+ cells. Compared to SRL, PRL had fewer CD4+ Tcells and more CD163+ macrophages. PRL1 had more CD68+ macrophages and Ki-67+ cells but less IFN-γ than GRL. PRL present a less efficient immune profile, which could explain the poor treatment response, while SRL had a more balanced immune response profile for lesion healing. Altogether, these evaluations suggest a differentiated profile of the organization of the inflammatory process for lesions of different tegumentary leishmaniasis evolution.

Citing Articles

Platelet-Derived Microvesicles Contribute to the Pathophysiogenesis of Human Cutaneous Leishmaniasis: A Nano-Flow Cytometric Approach in Plasma Samples from Patients before and under Antimonial Treatment.

Costa V, Chometon T, de Castro K, Ponte M, Pimentel M, Lyra M Microorganisms. 2024; 12(3).

PMID: 38543577 PMC: 10975300. DOI: 10.3390/microorganisms12030526.

References
1.
Maretti-Mira A, de Oliveira-Neto M, Da-Cruz A, de Oliveira M, Craft N, Pirmez C . Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression. Clin Exp Immunol. 2010; 163(2):207-14. PMC: 3043311. DOI: 10.1111/j.1365-2249.2010.04285.x. View

2.
Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S . IL-33 and IL-33 receptors in host defense and diseases. Allergol Int. 2010; 59(2):143-60. DOI: 10.2332/allergolint.10-RAI-0186. View

3.
Santos D, Coutinho C, Madeira M, Bottino C, Vieira R, Nascimento S . Leishmaniasis treatment--a challenge that remains: a review. Parasitol Res. 2008; 103(1):1-10. DOI: 10.1007/s00436-008-0943-2. View

4.
Heinzel F, Sadick M, Holaday B, Coffman R, Locksley R . Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989; 169(1):59-72. PMC: 2189187. DOI: 10.1084/jem.169.1.59. View

5.
Christensen S, Belew A, El-Sayed N, Tafuri W, Silveira F, Mosser D . Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis. PLoS Negl Trop Dis. 2019; 13(3):e0007152. PMC: 6405045. DOI: 10.1371/journal.pntd.0007152. View